ArticleAlzheimer's & dementia (New York, N. Y.)2018
Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial.
Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Intervention of ginseng-derived macromolecular drugs in Alzheimer's disease: exploring mechanisms and assessing potential.Frontiers in aging neuroscience · 2026Review
- Herb-Drug Interaction Between Sailuotong and Pitavastatin: A Systematic Pharmacokinetic Investigation and Mechanism Analysis.Drug design, development and therapy · 2025Article
- Efficacy of Sailuotong on neurovascular unit in amyloid precursor protein/presenilin-1 transgenic mice with Alzheimer's disease.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
- A review of SaiLuoTong (MLC-SLT) development in vascular cognitive impairment and dementia.Frontiers in pharmacology · 2024Review
- Review
- Article
- A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia.Aging medicine (Milton (N.S.W)) · 2022Article
- Combination ofFrontiers in pharmacology · 2022Article
- Crocins for Ischemic Stroke: A Review of Current Evidence.Frontiers in pharmacology · 2022Review
- Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective.Aging and disease · 2021Review
- Chinese Herbal Preparation SaiLuoTong Alleviates Brain IschemiaFrontiers in pharmacology · 2021Article
- Tianma Formula Alleviates Dementia via ACER2-Mediated Sphingolipid Signaling Pathway Involving AEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Involvement of 8-O-acetylharpagide for Ajuga taiwanensis mediated suppression of senescent phenotypes in human dermal fibroblasts.Scientific reports · 2020Article
- Association between serum NPTX2 and cognitive function in patients with vascular dementia.Brain and behavior · 2020Article
- Endothelium-Independent Vasodilatory Effect of Sailuotong (SLT) on Rat Isolated Tail Artery.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel.Journal of the American College of Cardiology · 2019 · on this mapReview
- Naomaitai Ameliorated Brain Damage in Rats with Vascular Dementia by PI3K/PDK1/AKT Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Sailuotong Capsule Prevents the Cerebral Ischaemia-Induced Neuroinflammation and Impairment of Recognition Memory through Inhibition of LCN2 Expression.Oxidative medicine and cellular longevity · 2019Article
- New Insights for Cellular and Molecular Mechanisms of Aging and Aging-Related Diseases: Herbal Medicine as Potential Therapeutic Approach.Oxidative medicine and cellular longevity · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNo licensed medications are available to treat vascular dementia (VaD).
methodsPatients were randomly assigned to experimental groups (SaiLuoTong [SLT] 360 or 240 mg for groups A and B for 52 weeks, respectively) or placebo group (SLT 360 mg and 240 mg for group C only from weeks 27 to 52, respectively).
resultsThree hundred twenty-five patients were included in final analysis. At week 26, the difference in VaD Assessment Scale-cognitive subscale scores was 2.67 (95% confidence interval, 1.54 to 3.81) for groups A versus C, and 2.48 (1.34 to 3.62) for groups B versus C (both DISCUSSION: This study suggests that SLT is effective for treatment of VaD, and this compound Chinese medicine may represent a better choice to treat VaD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.